Current treatment options |
Cholinesterase inhibitors, corticosteroids, Intravenous, Immunosuppressants, Immunoglobulins, bloodplasma transfer, Rituximab, Eculizumab, (ravulizumab)
|
References |
Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2
Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020;77(5):582-592. doi:10.1001/jamaneurol.2019.5125, (NCT03315130, fase 2) (1), Studie-opzet fase 3-studie (NCT04115293) (2); NCT03971422)
Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Neurol 2023; 22: 395–406.
|